

Supplemental Table S2. Characteristics of patients who underwent both cfDNA and tumor tissue genotyping testing.

Characteristic	Both cfDNA and tumor tissue genotyping testing (n=30)
Median age at MBC diagnosis	60
Subtype	
HR+/HER2-	29 (97%)
HR+/HER2+	1 (3.3%)
TNBC	0 (0%)
HR-/HER2+	0 (0%)
Type of MBC	
De Novo	5 (16.7%)
Recurrence	25 (83.3%)
Visceral Disease	15 (50%)
Non-visceral disease	15 (50%)
Median number of prior therapies before testing	
TG	1 (Range 0-8)
cfDNA	1 (Range 0-9)
TG and cfDNA testing	
Simultaneous	25 (83.3%)
Sequential	5 (16.7%)
Detectable mutations	
TG	24 (80%)
cfDNA	27 (90%)
Actionable mutations	
TG	19 (63.3%)
cfDNA	24 (80%)
Median number of actionable mutations	
TG	1 (Range 0-4)
cfDNA	2 (Range 0-11)
Failure of Assay	
TG	2 (6.7%)
cfDNA	0 (0%)